Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

Abstract excerpt

The mechanistic target of rapamycin (mTOR) drives several physiologic and pathologic cellular processes and is frequently deregulated in different types of tumors, including glioblastoma (GBM). Despite recent advancements in understanding the molecular mechanisms involved in GBM biology, the survival rates of this tumor are still disappointing, primarily due to the lack of efficacious treatments. The phosphatase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Histone Deacetylase Inhibitors Research
• Share to PI3K/AKT/mTOR signaling in cancer